A better understanding of the actions underlying the effects of IFN-β and its anti-inflammatory properties would help to clarify why IFN-β is not effective in all MS patients and to identify subjects that may benefit most from IFN-β treatment and those that should be directed to a therapy switch. This evidence concerns the gene IFNB1 and myeloid sarcoma.